CN101844970B - 具有生物活性的联苯环辛烯类木脂素衍生物 - Google Patents
具有生物活性的联苯环辛烯类木脂素衍生物 Download PDFInfo
- Publication number
- CN101844970B CN101844970B CN2010101824462A CN201010182446A CN101844970B CN 101844970 B CN101844970 B CN 101844970B CN 2010101824462 A CN2010101824462 A CN 2010101824462A CN 201010182446 A CN201010182446 A CN 201010182446A CN 101844970 B CN101844970 B CN 101844970B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- dibenzocyclooctene
- hepatitis
- hbv
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920005610 lignin Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 229930013686 lignan Natural products 0.000 claims abstract description 15
- 150000005692 lignans Chemical class 0.000 claims abstract description 15
- 235000009408 lignans Nutrition 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 241000700721 Hepatitis B virus Species 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 abstract description 14
- 239000000427 antigen Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 102000036639 antigens Human genes 0.000 abstract description 10
- 108091007433 antigens Proteins 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 0 Cc1c(C)c(-c2c(*)c(*)c(*)c(*)c2C*)c(C*)c(*)c1* Chemical compound Cc1c(C)c(-c2c(*)c(*)c(*)c(*)c2C*)c(C*)c(*)c1* 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000021028 berry Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000758724 Schisandraceae Species 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- ZKHSPLCIOVILMA-UHFFFAOYSA-N 2-(2-phenylphenyl)ethanol Chemical compound OCCC1=CC=CC=C1C1=CC=CC=C1 ZKHSPLCIOVILMA-UHFFFAOYSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- GFBYHDOAACQOHD-UHFFFAOYSA-N C1=CC=CC=2C=CC=CC3=C(C21)C=CC=C3.C=CCCCCCC.C3(CCCCC3)C3=C(C=CC=C3)C3=CC=CC=C3 Chemical compound C1=CC=CC=2C=CC=CC3=C(C21)C=CC=C3.C=CCCCCCC.C3(CCCCC3)C3=C(C=CC=C3)C3=CC=CC=C3 GFBYHDOAACQOHD-UHFFFAOYSA-N 0.000 description 1
- 101100139845 Caenorhabditis elegans rac-2 gene Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical class N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- -1 alkylammonium halides Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003632 chemoprophylactic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 108010064245 urinary gonadotropin fragment Proteins 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
编号 | 化合物数据 |
(S)-1 | [α]D 20:53.7(c 0.96,EtOAc);1H NMR(300MHz,CD3OD):δ(ppm)7.09(s,2H),4.24(s,2H),3.90(s,6H),3.84(s, 6H),3.66(s,6H)3.34(s,2H);13C NMR(75MHz,CDCl3)δ(ppm)156.59,154.84,145.23,138.70,120.24,107.14, 77.21,63.96,63.92,59.08;MALDI:392([M]+),415([M+Na]+);HRMS for[M++H](C20H24O8):calcd.392.1477, found:392.1466 |
(R)-1 | 1H NMR(300MHz,CD3OD):δ(ppm)7.09(s,2H),4.24(s,2H),3.90(s,6H),3.84(s,6H),3.66(s,6H)3.34(s,2H); 13C NMR(75MHz,CDCl3)δ(ppm)156.59,154.84,145.23,138.70,120.24,107.14,77.21,63.96,63.92,59.08; |
rac-1 | 1H NMR(300MHz,CD3OD):δ(ppm)7.09(s,2H),4.24(s,2H),3.90(s,6H),3.84(s,6H),3.66(s,6H)3.34(s,2H); 13C NMR(75MHz,CDCl3)δ(ppm)156.59,154.84,145.23,138.70,120.24,107.14,77.21,63.96,63.92,59.08; |
(S)-2 | 1H NMR(300MHz,CDCl3):δ(ppm)6.89(s,2H),4.18-4.17(d,4H),3.93(s,6H),3.8(s,6H),3.67(s,6H),3.14(s, 2H);ESI-MS(m/z,%):417.5([M+Na]+) |
(R)-2 | 1H NMR(300MHz,CDCl3):δ(ppm)6.89(s,2H),4.18-4.17(d,4H),3.93(s,6H),3.8(s,6H),3.67(s,6H),3.14(s, 2H);ESI-MS(m/z,%):417.5([M+Na]+) |
rac-2 | 1H NMR(300MHz,CDCl3):δ(ppm)6.89(s,2H),4.18-4.17(d,4H),3.93(s,6H),3.8(s,6H),3.67(s,6H),3.14(s, 2H);ESI-MS(m/z,%):417.5([M+Na]+) |
3 | EIMS(m/z,%):342(100),360(M+,71.54),343(23.10),313(19.35),361(15.97). |
4 | ESI-MS(m/z,%):623.4([M+Na]+);HRMS for[M++Na](C34H32O10):calcd.623.1895,found:623.1887 |
5 | 1H NMR(300MHz,CDCl3):δ(ppm)6.79(s,2H),4.79-4.70(q,4H),3.92(s,3H),3.89(s,3H),3.70(s,3H),2.01(s, 6H);ESI-MS(m/z,%):501.4([M+Na]+) |
6 | ESI-MS(m/z,%):499.5([M+Na]+) |
7 | 1H NMR(300MHz,CDCl3):δ(ppm)7.97-7.95(m,4H),7.51-7.47(m,2H),7.37-7.33(m,4H),3.90(s,6H),3.87(s, 6H),3.72(s,6H),2.01(s,6H);ESI-MS(m/z)625.6([M+Na]+) |
8 | 1H NMR(300MHz,CDCl3):δ(ppm)7.26-7.23(d,1H),7.19-7.17(m,2H),7.00-6.97(d,1H),6.92-6.88(m,3H), 4.94-4.90(d,1H),4.71-4.67(d,1H),4.22(s,2H),4.12(s,2H),3.93(s,3H),3.91(s,3H),3.81(s,3H),3.63(s,3H); |
9 | 1H NMR(300MHz,CDCl3):δ(ppm)7.35-7.30(m,4H),7.03(d,2H,J=8.4Hz),4.29(s,2H),3.87(s,6H),;13C NMR(75MHz,CDCl3)δ(ppm)156.18,140.08,127.95,119.21,115.44,110.88,73.39,54.94;ESI-MS(m/z,%): 295([M+Na]+) |
10 | 1H NMR(300MHz,CDCl3):δ(ppm)8.93(s,1H),7.16(s,1H),7.15-7.13(d,1H),6.88-6.86(d,1H),4.45-4.43(d, 1H),4.35-4.33(d,1H),3.92(s,3H),3.90(s,6H),3.77(s,2H),3.60(s,1H),2.11(s,1H);13C NMR(75MHz,CDCl3) δ(ppm)153.06,150.03,148.28,142.81,141.52,134.28,129.78,118.10,116.72,115.37,110.50,105.77,73.50, 62.67,61.35,60.42,56.03,55.78;ESI-MS(m/z,%):347.1([M-H]+),393.2([M-H+2Na]+) |
11 | 1H NMR(300MHz,CDCl3):δ(ppm)7.41-7.37(t,2H),7.17-7.15(d,2H),6.97-6.95(d,2H),4.27-4.19(q,4H), 3.70(s,6H),2.54(s,2H); |
15 | 1H NMR(300MHz,CDCl3):δ(ppm)6.88(s,1H),6.85(s,1H),6.13(s,1H),4.19-4.11(m,4H),3.91(s,6H),3.88(s, 6H),3.68(s,3H),3.58(s,3H); |
16 | 1H NMR(300MHz,CDCl3):δ(ppm)7.29-7.27(d,2H),7.17-7.14(m,6H),7.05-7.03(d,2H),6.87-6.85(m,4H), 4.93-4.91(d,2H),4.61-4.59(d,2H),4.26-4.16(q,4H),3.91(s,6H),3.00(s,2H); |
17 | 1H NMR(300MHz,CDCl3):δ(ppm)6.93(s,2H),6.27(br,2H),4.50(d,2H,J=14.1Hz),3.91(s,6H),3.88(s,6H), 3.74(s,6H),3.74(s,6H),1.41(s,18H);13C NMR(75MHz,CDCl3)δ(ppm)152.17,151.69,141.48,129.86,117.62, 104.50,61.06,60.98,58.46,57.16,56.07,23.02;ESI-MS(m/z,%):599([M+H]+)621([M+Na]+);HRMS for [M+Na]+(C28H42N2O8S2Na):calcd.621.2270,found:621.2275 |
19 | 1H NMR(300MHz,CDCl3):δ(ppm)7.70(d,2H,J=1.8Hz),7.50(d,2H,J=8.1Hz),7.32(dd,2H,J=1.8Hz,8.1Hz), 5.58(s,2H),4.77(s,2H),1.34(s,18H);13C NMR(75MHz,CDCl3)δ(ppm)134.61,134.42,133.27,128.53,128.36, 124.50,59.46,57.00,22.78;MALDI-TOF:487([M+H]+)509([M+Na]+);HRMS for [M+Na]+(C22H28N2O2S2Cl2Na):calcd.509.0858,found:509.0861 |
Claims (4)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101824462A CN101844970B (zh) | 2010-05-21 | 2010-05-21 | 具有生物活性的联苯环辛烯类木脂素衍生物 |
PCT/CN2011/074382 WO2011144054A1 (zh) | 2010-05-21 | 2011-05-20 | 联苯环辛烯类木脂素衍生物及其在治疗病毒性肝炎方面的应用 |
JP2013511519A JP2013531628A (ja) | 2010-05-21 | 2011-05-20 | ジベンゾシクロオクテン系リグナン誘導体及びそのウイルス性肝炎の治療における応用 |
KR1020127032614A KR20130087391A (ko) | 2010-05-21 | 2011-05-20 | 디벤조시클로옥텐계 리그난 유도체 및 그의 바이러스성 간염치료의 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101824462A CN101844970B (zh) | 2010-05-21 | 2010-05-21 | 具有生物活性的联苯环辛烯类木脂素衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101844970A CN101844970A (zh) | 2010-09-29 |
CN101844970B true CN101844970B (zh) | 2012-12-26 |
Family
ID=42769807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101824462A Expired - Fee Related CN101844970B (zh) | 2010-05-21 | 2010-05-21 | 具有生物活性的联苯环辛烯类木脂素衍生物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2013531628A (zh) |
KR (1) | KR20130087391A (zh) |
CN (1) | CN101844970B (zh) |
WO (1) | WO2011144054A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101844970B (zh) * | 2010-05-21 | 2012-12-26 | 上海常富药业有限公司 | 具有生物活性的联苯环辛烯类木脂素衍生物 |
CN102552285B (zh) * | 2012-01-17 | 2013-06-05 | 中国人民解放军第二军医大学 | 甘五酸在制备防治肝炎病毒药物中的应用 |
JP5874463B2 (ja) * | 2012-03-16 | 2016-03-02 | 住友化学株式会社 | 化合物および高分子化合物、並びに該高分子化合物を含む有機薄膜および有機半導体素子 |
CN103012520B (zh) * | 2012-12-28 | 2015-12-02 | 中国科学院上海有机化学研究所 | 抗乙肝病毒活性化合物菲糖苷类衍生物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101375842A (zh) * | 2007-08-27 | 2009-03-04 | 复旦大学 | 联苯环辛烯类木脂素在制备抗乙肝病毒药物中的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1284535C (zh) * | 2004-12-01 | 2006-11-15 | 普尔药物科技开发(深圳)有限公司 | 一种联苯环辛二烯木脂素在制备抗肿瘤药物的用途 |
CN101844970B (zh) * | 2010-05-21 | 2012-12-26 | 上海常富药业有限公司 | 具有生物活性的联苯环辛烯类木脂素衍生物 |
-
2010
- 2010-05-21 CN CN2010101824462A patent/CN101844970B/zh not_active Expired - Fee Related
-
2011
- 2011-05-20 WO PCT/CN2011/074382 patent/WO2011144054A1/zh active Application Filing
- 2011-05-20 KR KR1020127032614A patent/KR20130087391A/ko not_active Application Discontinuation
- 2011-05-20 JP JP2013511519A patent/JP2013531628A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101375842A (zh) * | 2007-08-27 | 2009-03-04 | 复旦大学 | 联苯环辛烯类木脂素在制备抗乙肝病毒药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2013531628A (ja) | 2013-08-08 |
WO2011144054A1 (zh) | 2011-11-24 |
KR20130087391A (ko) | 2013-08-06 |
CN101844970A (zh) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101844970B (zh) | 具有生物活性的联苯环辛烯类木脂素衍生物 | |
CN103181922A (zh) | 一类含哌啶酮的单羰基姜黄素类化合物在制备抗炎药物中的应用 | |
CN106866572B (zh) | 一氧化氮供体型β‑榄香烯衍生物及其制备方法和用途 | |
CN110668936B (zh) | 一种超声提取土沉香叶中二苯甲酮类化合物的方法 | |
CN102134245A (zh) | 四氢异喹啉类化合物及其制备方法和用途 | |
CN102260260A (zh) | 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途 | |
CN108752208B (zh) | 咖啡酰奎宁酸类化合物的提取方法及其产物和应用 | |
CN101012227A (zh) | 具有抗肿瘤作用的13-正-辛基小檗碱新衍生物 | |
CN103524318B (zh) | 一类含烯丙基的单羰基姜黄素类似物在制备抗炎药物中的应用 | |
CN101200743B (zh) | 水合淫羊藿素的制备方法 | |
CN110128482A (zh) | 一种具有肿瘤靶向的新型Pt(IV)配合物的制备方法及其应用 | |
CN102010398A (zh) | 含氮类联苯化合物,含其的药物组合物,其制备方法及其在抗hiv-1中的应用 | |
CN101385749A (zh) | 臭椿提取物在制备抗肿瘤药物中的应用 | |
CN105198714B (zh) | 杨梅醇衍生物及其制备方法和应用 | |
CN104610233A (zh) | 具有更高蛋白激酶g抑制活性的化合物及其制备方法 | |
CN107739381A (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
CN113549046B (zh) | 一种双联苄地钱素s衍生物及其制备方法和应用 | |
KR100884489B1 (ko) | 1,3,5-트리아진-4-일-디카르보-클로소-도데카보란 유도체,이의 제조방법 및 이를 포함하는 약학적 조성물 | |
CN107382944B (zh) | 一类具有抗肿瘤活性的香豆素棉酚衍生物及其合成方法 | |
CN101851196B (zh) | 2-(1h)喹啉酮衍生物,其药物组合物及其制备方法和用途 | |
CN111825608A (zh) | 四氢喹啉类与四氢异喹啉类化合物及其用途 | |
CN104530062B (zh) | 一种1,4-萘醌衍生物及其合成方法 | |
CN1271063C (zh) | 双(5-甲酰基糠基)醚衍生物、制备方法及药学的应用 | |
CN106432031A (zh) | 苯甲酸三氮唑类抗流感病毒化合物及其制备方法和用途 | |
CN101347475B (zh) | 羊角棉提取物在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI CHANGFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY OF CHINESE ACADEMY OF SCIENCES Effective date: 20120717 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 XUHUI, SHANGHAI TO: 200052 CHANGNING, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120717 Address after: 200052, 8B, 8C, room 1, 1448 lane, West Yan'an Road, Shanghai, Changning District Applicant after: Shanghai Changfu Pharmaceutical Co., Ltd. Address before: 200032 Shanghai city Xuhui District Fenglin Road No. 354 Applicant before: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI YSY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI CHANGFU PHARMACEUTICAL CO., LTD. Effective date: 20150212 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200052 CHANGNING, SHANGHAI TO: 201318 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150212 Address after: 201318 Shanghai city Pudong New Area inntech Road No. 139 Patentee after: Shanghai Yishengyuan Pharmaceutical Co., Ltd. Address before: 200052, 8B, 8C, room 1, 1448 lane, West Yan'an Road, Shanghai, Changning District Patentee before: Shanghai Changfu Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121226 Termination date: 20200521 |